Month: July 2013

The Future of HIV Treatment is Here: Once-a-Month Injections to Replace Daily Oral Medications

Leave a Comment / Blogger, Uncategorized / By

A combination of antiretroviral drugs in long-acting nanosuspension formulations achieved adequate blood levels and appeared safe in HIV negative study volunteers, offering the potential for a maintenance or PrEP option that could be taken once monthly, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. While modern antiretroviral therapy is highly safe and …

The Future of HIV Treatment is Here: Once-a-Month Injections to Replace Daily Oral Medications Read More »

Calimmune Initiates HIV Stem Cell Study at Two California Research Sites

Leave a Comment / Blogger, Uncategorized / By

(Los Angeles, CA) — The HIV gene medicines company Calimmune announced today that the first patient has begun treatment in a Phase I/II clinical trial designed to determine whether a pioneering genetic medicine approach can help to protect individuals infected with HIV from the effects of the virus. The study, “Safety Study of a Dual …

Calimmune Initiates HIV Stem Cell Study at Two California Research Sites Read More »

Two More Patients Are Cured of HIV- And This Time With A Less Complex Regimen

Leave a Comment / Blogger, Uncategorized / By

“Both the surviving patients had been receiving prolonged antiretroviral therapy and received stem cell transplants with a reduced-intensity conditioning regimen of chemotherapy designed to eradicate the cancer and eliminate the existing bone marrow. In the case of the two patients under investigation, the conditioning regimen did not include radiotherapy and it did not eliminate the …

Two More Patients Are Cured of HIV- And This Time With A Less Complex Regimen Read More »

New HIV Eradication Study: The Use of a Personalized ImmuneTherapy (AGS-004) with a Reservoir Activating Agent

Leave a Comment / Blogger, Uncategorized / By

Argos Therapeutics Announces Plans for HIV Eradication Study  “To create AGS-004, ribonucleic acid (RNA) is isolated from HIV particles obtained from patients, and dendritic cells are generated from a single leukapheresis procedure. Selected RNAs are then used to “program” the dendritic cells with the patient-specific payload to trigger an immune response against the patient’s HIV …

New HIV Eradication Study: The Use of a Personalized ImmuneTherapy (AGS-004) with a Reservoir Activating Agent Read More »